ATS 2023 International Conference
Welcome ATS Attendee
This page provides you information on Pliant Therapeutics’ investigational drug candidate, bexotegrast (previously known as PLN-74809), and its clinical program in patients with idiopathic pulmonary fibrosis (IPF).
About Pliant
Pliant Therapeutics is a clinical-stage biopharmaceutical company with expertise in fibrosis biology and deep focus on discovering and developing novel targeted therapies to address life-threatening fibrotic diseases.
About Bexotegrast
Bexotegrast is an investigational drug and is currently being evaluated in clinical trials as a potential treatment for IPF. The safety and effectiveness of bexotegrast has not yet been established and the FDA has not approved bexotegrast for any indication.
Bexotegrast is a small molecule, dual selective inhibitor of integrins αvβ6 and αvβ1 designed to block the activated form of TGF-β in fibrotic tissues. The blocking of TGF-β may prevent the activation of profibrotic signaling pathways in IPF.
Bexotegrast –
Phase 2a Clinical Trial Summary
INTEGRIS-IPF was a Phase 2a multinational, dose-ranging, randomized, double-blind, placebo-controlled clinical trial studying bexotegrast across 4 dose groups (40 mg, 80 mg, 160 mg and 320 mg) in 119 patients with IPF. The 12-week interim data from the study are being presented at ATS 2023.
Longer follow up data from the INTEGRIS-IPF study (24-week data from the 320 mg dose group) were recently announced and Pliant plans to present them at a future conference.
Next Steps in Evaluating Bexotegrast
as a Potential Treatment in IPF
Pliant is planning to initiate BEACON-IPF, a 52-week, multinational, double-blind, randomized, placebo-controlled Phase 2b clinical trial of bexotegrast at doses of 160 mg and 320 mg in approximately 270 patients with IPF, in mid-2023.
If you have questions about the bexotegrast program or would like to be considered as a clinical trial site for BEACON-IPF, please contact Pliant at [email protected].
Contact us